Neurosoft Bioelectronics is a neurotechnology company developing stretchable and scalable brain-computer interfaces. Its proprietary soft, stretchable electrode platform provides full-cortical access without penetrating brain tissue, enabling high-quality neural data acquisition. The company is headquartered in Geneva, Switzerland and has a US subsidiary in New York.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $7.5 M | May, 2026 | seed |
Frequently Asked Questions
Where is Neurosoft Bioelectronics located?
Neurosoft Bioelectronics is located in Geneva, Switzerland.
What industries does Neurosoft Bioelectronics operate in?
Neurosoft Bioelectronics operates in the following industries: neurotechnology, brain-computer interfaces, medical devices.
How much total funding has Neurosoft Bioelectronics raised?
Neurosoft Bioelectronics has raised a total of $7,500,000.
Who are the investors in Neurosoft Bioelectronics?
The investors in Neurosoft Bioelectronics are: Skybound Venture Capital, PL Capital, IAG Capital Partners, Connecticut Innovations.
What is the primary mission of Neurosoft Bioelectronics?
The mission of Neurosoft Bioelectronics is to build minimally invasive brain interfaces to monitor, treat, and restore lost functions for individuals fighting neurological disorders.
What kind of technology does Neurosoft Bioelectronics develop?
Neurosoft Bioelectronics develops soft, stretchable, and high-resolution implantable electrodes and brain-computer interfaces (BCIs) that conform to the brain's surface to achieve long-term bio-integration while reducing surgical risks.
What medical conditions is Neurosoft Bioelectronics focused on treating?
Neurosoft Bioelectronics is primarily focused on developing solutions for severe neurological disorders, including severe tinnitus and drug-resistant epilepsy.
Where is Neurosoft Bioelectronics headquartered?
Neurosoft Bioelectronics is headquartered in Geneva, Switzerland, and also maintains a presence in New York.
How does the technology from Neurosoft Bioelectronics differ from conventional electrodes?
The brain interfaces from Neurosoft Bioelectronics are significantly thinner and 1,000 to 100,000 times softer than conventional electrodes, allowing them to better conform to neural tissue, reduce scar tissue formation, and minimize risks like subdural hematomas.
When was Neurosoft Bioelectronics founded?
Neurosoft Bioelectronics was founded in 2019 as a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL).